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Abstract: Ovarian hormones, such as estrogens and progesterone, are known to exert beneficial
effects on cognition and some psychiatric disorders. The basis of these effects is not fully understood,
but may involve altered cholinergic neurotransmission. This study aimed to investigate how a
lack of ovarian hormones would impact muscarinic receptor-induced deficits in prepulse inhibition
(PPI) and muscarinic receptor density in several brain regions. Adult female rats were either
ovariectomized, to remove the source of ovarian hormones, or left intact (sham-operated). PPI is
a measure of sensorimotor gating that is typically impaired in schizophrenia patients, and similar
deficits can be induced in rats by administering scopolamine, a muscarinic receptor antagonist. Our
results revealed no significant effects of ovariectomy on PPI after saline or scopolamine treatment.
Autoradiography was performed to measure cholinergic muscarinic receptor binding density using
[3H]-pirenzepine, [3H]-AF-DX, and [3H]-4-DAMP, to label M1, M2/M4, and M3 receptors, respectively.
We examined the amygdala, caudate putamen, dorsal hippocampus, motor cortex, retrosplenial cortex,
and ventromedial hypothalamus. There were no significant group differences in any region for any
muscarinic receptor type. These results suggest that removing peripheral ovarian hormones does not
influence the cholinergic muscarinic receptor system in the context of PPI or receptor binding density.
Keywords: ovariectomy; female; rat; schizophrenia; PPI; CHRM1
1. Introduction
Current data suggest that female ovarian hormones can improve cognitive function [1–3] and
reduce symptom severity in neuropsychiatric disorders, such as schizophrenia [4]. For instance,
epidemiological evidence indicates that, compared to women, there is a higher incidence and earlier
Brain Sci. 2020, 10, 106; doi:10.3390/brainsci10020106 www.mdpi.com/journal/brainsci
Brain Sci. 2020, 10, 106 2 of 12
onset of schizophrenia in men [5]; the latter phenomenon is consistent across cultures and independent
of the diagnostic classification system used [6–8]. There is also evidence to suggest that the impact
of ovarian hormones on the symptoms of schizophrenia varies across the reproductive lifespan of
women, which is underscored by changing levels of hormones, including the main ovarian hormones,
estrogen and progesterone [8–10]. Overall, these factors lead to a less severe course of illness, milder
symptoms, and superior treatment outcomes in women.
Cholinergic signaling plays a crucial role in multiple cognitive processes, including learning,
memory, and sensory perception [11]. Converging lines of evidence have implicated muscarinic
cholinergic signaling in the pathophysiology of schizophrenia. In patients with schizophrenia, in vivo
muscarinic receptor availability was reduced [12,13], and postmortem radioligand binding studies
using [3H]-pirenzepine, which label muscarinic M1 and M4 receptors, have indicated that the densities
of these receptors were decreased in the prefrontal cortex, anterior cingulate cortex, hippocampus,
and caudate putamen of schizophrenia patients [14–18]. Notably, decreased levels of both M1
mRNA levels [17,19,20] and M1 receptor protein, but not M2, M3, or M4 receptor protein [17,21],
were observed in the dorsolateral prefrontal cortex and superior prefrontal gyrus from people with
schizophrenia. These data suggest that low levels of cortical M1 receptors are a significant component
of the pathophysiology of schizophrenia.
Scopolamine is a nonselective muscarinic receptor antagonist that induces a host of cognitive
and psychotic symptoms referred to as “anti-muscarinic syndrome”, which resembles some clinical
aspects of schizophrenia [22,23]. In rodents, administration of scopolamine is known to induce
deficits in prepulse inhibition (PPI) [24–26], which has been proposed as an antimuscarinic model of
schizophrenia [27]. PPI is the attenuation of the acoustic startle response to an intense audiogenic
stimulus (pulse) by a preceding, weaker acoustic stimulus (prepulse). PPI is used as an operational
measure of sensorimotor gating, a process which is deficient in schizophrenia, and can be measured
with analogous methods in rodents [28–30].
We and others have previously investigated the effects of ovariectomy, ovarian hormones, and
their synthetic analogues in PPI [31–35]. For example, while ovariectomy had no effect on PPI [31–33],
treatment with the estrogen, 17β-estradiol, could reverse PPI deficits that were induced by serotonin
1A (5-HT1A) receptor agonists in both female rats [32] and healthy women [36]. Specifically, chronic
high-dose estradiol treatment prevented the disruptions in PPI induced by the 5-HT1A receptor agonist
8-hydroxy-dipropylaminotertralin (8-OH-DPAT) in rats [32]. Similarly, estradiol treatment in healthy
women abolished the deficits in PPI induced by the partial 5-HT1A receptor agonist, buspirone [36].
Subsequent pharmacological studies in rats indicated that chronic estradiol treatment inhibited the
effects of 8-OH-DPAT and the dopamine D1/D2 receptor agonist, apomorphine, on PPI, and that
the protective effects of estrogen on PPI were at least partly dependent on dopamine D2 receptor
signaling down-stream of 5-HT1A receptor signaling [37]. Collectively, these findings implicate ovarian
hormones, particularly estradiol, in the regulation of PPI. The impact of removal of ovarian hormones
on PPI deficits induced by cholinergic muscarinic receptor agonists has not been previously examined.
Given that both muscarinic receptors and ovarian hormones are implicated in the mediation of
PPI, the aim of this study was to assess the effects of ovariectomy on scopolamine-induced deficits in
PPI and binding density of muscarinic receptors in the CNS in rats.
2. Materials and Methods
2.1. Animals
In total, 35 female Sprague-Dawley rats were used in this study. Rats were obtained from a
commercial supplier (Animal Resources Centre; Perth, WA, Australia) when they were 9–10 weeks old
and housed in open top cages in groups of 2–3 per cage with access to standard rat chow and water ad
libitum. Rats were housed on a 12-hour light-dark cycle (lights on at 6 a.m.) at constant temperature of
23 ± 2 ◦C. All experimental procedures were approved by the Florey Institute of Neuroscience and
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Mental Health Animal Ethics Committee and were performed in accordance with the Australian Code
of Practice for the Care and Use of Animals for Scientific Purposes.
2.2. Ovariectomy
At 11-12 weeks of age, rats were either left intact (sham-operated) or ovariectomized (OVX;
n = 10 per group) as reported previously [37]. For surgical procedures, rats were anaesthetized
with isoflurane/oxygen gas mixture and injected with analgesic anti-inflammatory agent, carprofen
(Rimadyl, Pfizer, 5 mg/kg; West Ryde, NSW, Australia), to reduce postoperative pain. A 2–3 cm
incision was made through the skin and abdominal wall on the lower medial region of the dorsal
surface. The ovaries were located, and the ovaries were then bilaterally removed in the OVX rat group
only. The wound was closed using two surgical sutures and covered with antiseptic cream (Betadine,
povidone-iodine 10%, Faulding Consumer; Salisbury, SA, Australia). Rats were given 10 days to
recover before further experimentation.
2.3. Prepulse Inhibition (PPI)
PPI was measured using automated startle chambers (San Diego Instruments, San Diego, CA,
USA), as described previously [37]. In brief, rats were placed in a transparent Plexiglas cylinder that sat
within a sound-attenuating cabinet. Audiogenic stimuli were delivered with a speaker, and whole-body
startle responses were measured using the automated SR-Lab software (San Diego Instruments). The
30-minute session consisted of 80 trials presented at variable intervals (8–27 s), 8 no tone (i.e., only
background, 70 dB), 32 pulse-alone (4 blocks of 8 × 115 dB) trials, and 40 prepulse trials (8 of each:
2, 4, 8, 12, or 16 dB above background followed 100 ms later by the 115 dB pulse). Startle data were
measured using all four blocks of pulse-alone trials. The percentage of PPI was calculated as the
difference in amplitude between the startle response to the pulse-alone trials and the prepulse-pulse
trials, divided by the response to the pulse-alone trial × 100%.
Saline or 0.3 mg/kg scopolamine (Scopolamine hydrobromide trihydrate; Sigma-Aldrich, St. Louis,
MO, USA) was administered subcutaneously 30 min prior to PPI testing. Scopolamine was dissolved
in saline to a dose based on previous literature [25,38] and administered in a volume of 1 ml/kg.
Using a randomized, crossover protocol, rats received both treatments with 3–4 days allowed between
each experiment.
2.4. Autoradiography
In a separate cohort of intact (sham-operated) (n = 7) or OVX (n = 8) rats (procedure as described
above), frozen whole brains were blocked, and serial coronal 20 µm sections were sectioned on a
cryostat (Leica CM18-50, Leica Microsystems Nussloch GmbH, Germany) and thaw mounted onto
gelatinized microscope slides. Sections were collected aiming for bregma −2.76 mm [39], such that the
following regions could be traced for the left and right hemispheres: retrosplenial cortex (granular and
dysgranular), motor cortex (M1 and M2 combined), dorsal hippocampus, ventral caudate putamen,
central amygdala, basolateral amygdala, medial amygdala, and ventromedial hypothalamus (Figure 1).
Due to issues with sectioning and damaged tissue, we were unable to collect a measurement for each
region for each rat, thus the final sample was n = 3–8 per group.
Under the conditions used in this study, [3H]-pirenzepine would provide a measure of M1
receptors [40], [3H]-AF-DX 384 would provide a measure of M2 and M4 receptors [41], and [3H]-4-DAMP
(4-diphenylacetoxy-N-methylpiperidine methiodide) would provide a measure of M3 receptors [42].
For all three radioligands (PerkinElmer, Waltham, MA, USA), three sections per animal were used to
measure total radioligand binding, and two sections per animal were used to measure nonspecific
binding (Figure 2).
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Figure 1. Example autoradiographic image of [3H]-AF-DX binding showing the traced outlines of
the nine regions of interest: (1) retrosplenial cortex (granular), (2) retrosplenial cortex (dysgranular),
(3) motor cortex (M1, M2), (4) dorsal hippocampus, (5) caudate putamen, (6) central amygdala, (7)
basolateral amygdala, (8) medial amygdala, and (9) ventromedial hypothalamus.
Figure 2. Representative autoradiographic images showing total binding (left panels) and nonspecific
binding (right panels). Three tritiated radioligands were used with the protocols described in Section 2.4.
For [3H]-pirenzepine binding, tissue sections were incubated in assay buffer (10 mM KH2PO4, 10
mM Na2HPO4; pH 7.4) containing 25 nM [3H]-pirenzepine in the presence or absence of 1 µM QNX
(3-quinuclidinyl xanthene-9-carboxylate hemioxalate; Sigma-Aldrich) for 30 min at room temperature.
[3H]-AF-DX 384 binding was measured after incubating tissue sections in assay buffer (10 mM KH2PO4,
10 mM Na2HPO4; pH 7.4) for 30 min at room temperature. The tissue sections were then dipped
in distilled water and air-dried. Sections were next incubated in assay buffer containing 24 nM
[3H]-AF-DX 384 in the absence (total binding) or presence (nonspecific binding) of 1 µM tropicamide
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(Tocris Bioscience, Bristol, UK) for 60 min at room temperature. For both radioligands, tissue sections
were then washed twice for 2 min in ice-cold assay buffer, dipped in ice-cold distilled water, dried,
partially fixed in paraformaldehyde vapor overnight, and then apposed to a BAS-TR2025 plate (Fujifilm,
Tokyo, Japan) with autoradiographic tritium standards (American Radiolabeled Chemicals, St. Louis,
MO, USA) for 3 ([3H]-pirenzepine) or 7 ([3H]-AF-DX 384) days.
For [3H]-4-DAMP binding, tissue sections were incubated in assay buffer (50 mM Tris-HCl; pH 7.4)
for 15 min at room temperature, dipped in distilled water, and air-dried. Sections were then incubated
in assay buffer containing 60 nM [3H]-4-DAMP and 1 µM pirenzepine dihydrochloride (to displace
M1 receptors) in the absence (total binding) or presence (nonspecific binding) of 10 µM 4-DAMP
mustard for 60 min at room temperature. After radioligand binding, slides were washed twice for
5 min in ice-cold assay buffer, dipped in ice-cold distilled water, dried, partially fixed overnight in
paraformaldehyde vapor, and apposed to a BAS-TR2025 plate with autoradiographic tritium standards
for 3 days.
In all cases, the BAS-TR2025 plates were scanned in a BAS 5000 high resolution phosphoimager
(Fujifilm, Tokyo, Japan). The resulting images were analyzed using AIS imaging software (Imaging
Research, St. Catharines, ON, Canada). Radioligand binding was measured as an integrated
measurement of signal intensity across the entire region of binding, including both hemispheres. Signal
intensities were calibrated against the standards and expressed as the average amount of total bound
radioligand (fmol/mg) estimated tissue equivalent (ETE) minus the average nonspecific binding for
each rat [43].
2.5. Statistical Analysis
All data are expressed as mean ± standard error of the mean (S.E.M.) and were analyzed using
IBM SPSS Statistics for Windows, Version 26 (IBM Corp., Armonk, NY, USA). Differences between
groups were considered significant if p < 0.05. Group differences in body and uterus weights were
analyzed using unpaired t-tests. For PPI, a 2 group (intact, OVX) x 2 drug (saline, scopolamine) ×
5 prepulse intensity (PP2–PP16) three-way repeated-measures analysis of variance (ANOVA) was
used. For startle amplitude, a 2 group (intact, OVX) × 2 drug (saline, scopolamine) × 4 block (4 ×
8 pulse-alone trials) three-way ANOVA was used. For graphical presentation only, average startle
amplitudes were used. Group differences in muscarinic receptor binding density were analyzed using
separate unpaired t-tests for each receptor in each brain region.
3. Results
3.1. Ovariectomy
At the time of surgery, body weights did not differ between the groups (Intact: 258 ± 6 g, OVX:
254 ± 4 g; t(18) = 0.47, p = 0.64). Consistent with our prior studies [37], at the end of experimentation,
OVX rats had significantly greater body weight (Intact: 307 ± 11 g, OVX: 361 ± 13 g; t(18) = −3.22, p =
0.005) than intact rats. OVX rats also had significantly smaller uteri when expressed as an absolute
weight (Intact: 0.61 ± 0.04 g, OVX: 0.11 ± 0.00 g; t(18) = 11.30, p < 0.001) or as a percentage of body
weight (Intact: 0.20 ± 0.01 %, OVX: 0.03 ± 0.00 %; t(18) = 11.33, p < 0.001). These findings confirmed
the effectiveness of the OVX surgery.
3.2. Prepulse Inhibition
When comparing PPI in intact and OVX rats that were administered saline or 0.3 mg/kg scopolamine
(2 group × 2 dose × 5 prepulse intensity ANOVA; Figure 3), the main effect of prepulse intensity was
observed (F(4,72) = 94.18, p < 0.001), reflecting an increase in PPI with increasing prepulse intensity.
The main effect of drug was observed (F(1,18) = 51.20, p < 0.001), reflecting the disruption of PPI caused
by scopolamine treatment in intact rats (F(1,9) = 45.41, p < 0.001) and OVX rats (F(1,9) = 15.49, p =
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0.003; Figure 3). No main effect of group, or any interactions of group and drug or prepulse intensity,
were detected, reflecting a similar disruption in PPI in both groups.
Figure 3. Prepulse inhibition (PPI; graphs A and B) and startle responses (graph C) in intact or
ovariectomized (OVX) rats (n = 10 per group). Rats were tested after treatment with saline (white bars)
or 0.3 mg/kg scopolamine (grey bars). Individual data are depicted by open circles (saline) or black
squares (scopolamine). %PPI refers to the difference in startle between the pulse-alone trials and the
prepulse-pulse trials, divided by the response to the pulse-alone trial × 100%. Prepulse intensity (PP)
refers to the trials that were 2, 4, 8, 12, or 16 dB above the 70 dB background noise followed 100 ms later
by the 115 dB startling pulse. Startle amplitude refers to the average of the four blocks of eight 115 dB
startling pulses. Bars represent mean ± S.E.M.
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When comparing startle amplitude between groups (2 group × 2 drug × 4 block ANOVA), no
significant effects or interactions were observed, reflecting similar startle amplitudes in both groups,
with or without scopolamine and over the duration of the PPI session (Figure 3). Thus, the PPI results
were not affected by a change in startle amplitude.
3.3. Receptor Binding Autoradiography
There were no significant differences in [3H]-pirenzepine, [3H]-AF-DX, or [3H]-4-DAMP binding
density in any of the nine brain regions between intact and OVX rats (Table 1). A trend for reduced
[3H]-AF-DX binding density was observed in the hippocampus of OVX rats compared to intact rats
(t(6) = 2.30, p = 0.061). There was also a trend for reduced [3H]-4-DAMP binding density in the central
amygdala of OVX rats compared to intact rats (t(7) = 2.19, p = 0.065).
Table 1. Mean (S.E.M.) cholinergic muscarinic receptor binding density (fmol/mg estimated tissue
equivalent) in intact and ovariectomized (OVX) rats in nine brain regions (n = 3–8 per group).
[3H]-Pirenzepine, [3H]-AF-DX 384, and [3H]-4-DAMP were used to label M1, M2/M4, and M3
receptors, respectively.
[3H]-Pirenzepine [3H]-AF-DX [3H]-4-DAMP
INTACT OVX INTACT OVX INTACT OVX
Retrosplenial cortex (granular) 66.4 (1.7) 64.9 (2.3) 77.1 (3.0) 75.1 (3.4) 71.4 (3.6) 79.0 (4.9)
Retrosplenial cortex (dysgranular) 89.7 (3.4) 84.2 (6.3) 81.0 (4.3) 82.3 (4.8) 91.8 (4.6) 90.5 (6.4)
Motor cortex (M1, M2) 105.5 (5.2) 108.1 (5.8) 92.6 (6.5) 92.2 (3.0) 124.0 (13.4) 134.8 (17.8)
Dorsal hippocampus 93.3 (14.4) 82.2 (11.4) 71.9 (2.6) 61.2 (4.4) 82.2 (5.8) 76.6 (3.3)
Caudate putamen (ventral) 91.4 (9.0) 94.4 (7.5) 89.6 (2.8) 96.9 (4.1) 120.2 (16.7) 122.7 (16.9)
Central amygdala 97.5 (9.7) 82.3 (2.2) 68.2 (2.6) 60.7 (4.4) 78.1 (2.4) 65.8 (4.6)
Basolateral amygdala 126.3 (7.5) 114.2 (2.5) 96.7 (7.4) 90.5 (6.6) 77.8 (5.1) 81.6 (6.6)
Medial amygdala 73.0 (3.1) 70.3 (3.1) 58.1 (2.4) 54.5 (3.1) 72.4 (5.2) 61.8 (4.7)
Ventromedial hypothalamus 18.9 (1.3) 19.7 (2.6) 31.3 (3.3) 27.5 (5.4) - -
4. Discussion
In this study, we aimed to investigate the effects of ovariectomy on scopolamine-induced PPI
deficits and cholinergic muscarinic receptor binding density to assess potential interactions between
ovarian hormones and muscarinic receptors. We did not observe any effects of ovariectomy on
scopolamine-induced impairments in PPI, nor did we detect any significant changes in the binding
density of M1, M2/M4, and M3 receptors in the amygdala, caudate putamen, dorsal hippocampus,
motor cortex, retrosplenial cortex, or ventromedial hypothalamus of OVX rats relative to intact rats.
These results suggest that muscarinic receptor antagonist-induced PPI deficits are independent of
ovarian hormone status. To our knowledge, this study is the first to examine scopolamine-induced
PPI deficits in female rats and to systematically assess the effects of eliminating circulating ovarian
hormones on M1, M2/M4, and M3 receptor density in the female rat brain.
Past research has highlighted an interaction between estrogen and the muscarinic system. For
instance, ovariectomy attenuates high-affinity choline uptake and acetylcholine synthesis in cerebral
cortical synaptosomes [44]. Estrogen receptors are densely expressed in the basal forebrain, which
provides major cholinergic input to the hypothalamus, hippocampus, and cortex [45,46]. Further,
muscarinic receptor binding fluctuates across the estrous cycle [47], and ovariectomy upregulates
M4 receptors in the hippocampus, frontal cortex, and hypothalamus, an effect that was normalized
by estrogen, but not progesterone, treatment [48]. In humans, chronic estrogen therapy in women
was associated with greater cholinergic responsivity and significantly higher M1 and M4 receptor
density compared to that in women who were naïve to estrogen therapy [49,50]. Based on these
findings, we hypothesized that removal of estrogen would modulate muscarinic receptor expression in
nine specific brain regions, namely, the granular and dysgranular retrosplenial cortex; motor cortex;
dorsal hippocampus; caudate putamen; amygdaloid regions including the central, basolateral, and
medial nuclei; and ventromedial hypothalamus. These regions were selected for anatomical and
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functional reasons, as they express a high density of muscarinic receptors and are implicated in various
sensorimotor and cognitive processes. For instance, the retrosplenial cortex plays a crucial role in spatial
and episodic memory, navigation, and planning for the future [51]. The retrosplenial cortex receives
dense cholinergic innervation from the basal forebrain, and the loss of such cholinergic inputs induces
upregulation of muscarinic receptors in this region [52]. In the dorsal hippocampus, more than 90% of
nonpyramidal/GABAergic neurons express muscarinic receptors [53]. Moreover, muscarinic receptor
signaling in the dorsal hippocampus is critical for memory consolidation [54]. Indeed, muscarinic
receptor levels are decreased in the hippocampal formation of schizophrenia patients relative to healthy
controls [15], most likely due to low levels of M4 receptor expression [55], whilst [3H]-AF-DX binding is
reduced in the caudate putamen of schizophrenia patients [41] in the absence of changes in M1 and M2
receptor expression [20]. The amygdaloid complex, especially the central amygdala, also expresses a
high density of muscarinic receptors [56]. Estradiol treatment dose-dependently increased muscarinic
receptor binding in the ventromedial hypothalamus of OVX female rats, whereas muscarinic receptor
binding was not altered in vehicle-treated OVX female rats or estradiol-treated male rats [57]. Although
the above literature highlights an interaction between estrogen and the muscarinic system, the precise
role of estrogen and other ovarian hormones in cholinergic signaling is unclear and likely involves a
complex modulatory role of ovarian hormones on multiple systems.
In the present study, we did not observe any significant changes in M1, M2/M4, or M3 receptor
binding density in OVX rats relative to intact rats in any of the brain regions examined, suggesting that
removal of ovarian hormones does not directly impact muscarinic receptor density in these brain regions
in adult female rats. Studies have assessed the effects of ovariectomy on the expression of muscarinic
receptor subtypes (M1 to M5) but have largely focused on the rat hippocampus [58–60]. In contrast to
our findings, one study reported that ovariectomy augmented the protein expression of all muscarinic
receptor subtypes compared to control in whole hippocampal homogenates from Wistar rats [58].
Various methodological differences may explain this discrepancy; our study measured individual
muscarinic receptors, in the dorsal hippocampus, using tissue sections from Sprague-Dawley rats.
Nevertheless, we observed a trend for reduced M2/M4 receptor binding density in the hippocampus
of OVX rats relative to intact rats. Pharmacological and behavioral studies have implicated the
importance of M2 receptors in learning and memory task performance [61,62]. The trend for reduced
hippocampal M2/M4 receptor binding partly supports past observations that ovariectomy affects
hippocampal-dependent learning and memory in rats. Indeed, the positive effects of estrogen on
working memory are dependent on M2 receptor hippocampal signaling [63].
In humans, ovarian hormones have been demonstrated to affect PPI [36], with lower PPI in
females than in males, and reduced PPI in women during the luteal phase when circulating estradiol
and progesterone are elevated [64–66]. We have previously demonstrated that estradiol treatment has
a protective effect on disruptions of PPI induced by the 5-HT1A receptor agonist; 8-OH-DPAT; and
dopamine receptor agonist, apomorphine [32,36]. We therefore assessed whether removal of the major
source of circulating estrogen would impact deficits in PPI induced by the nonselective muscarinic
receptor antagonist, scopolamine. However, we did not observe any differences in scopolamine-induced
deficits in PPI between OVX and intact rats. Our results suggest that scopolamine-induced impairments
in PPI are not mediated by ovarian hormones, given that the elimination of circulating ovarian hormones
did not significantly alter PPI. The absence of behavioral effects was consistent with the lack of alterations
in muscarinic receptor binding density observed in this study. Ovariectomy removes the main source
of estradiol, progesterone, and other ovarian hormones from the periphery. Thus, the lack of effect
observed here could be due to the role of progesterone (or other hormones) masking the effects of
estradiol, as progesterone could be exerting contrasting effects to those induced by estradiol [10].
Additionally, central production of these hormones may have partly compensated for the reduction in
peripheral levels of these hormones. Further research is needed to determine the exact role of each
ovarian hormone. It would also be of interest to determine if ovarian hormones influence muscarinic
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receptor activation, as the M1/M4 receptor agonist, xanomeline, has been shown to be efficacious in the
treatment of schizophrenia [67].
A limitation of the binding results is that several tissue samples were damaged, and we were
unable to collect a measurement for every single region in each rat. As such, group sample sizes
were unequal and some groups had small sample size (n = 3–8), which limits the generalizability of
these findings. Future research should repeat these experiments with larger sample sizes to increase
statistical power and improve signal detection. Another limitation is that we did not control for estrous
cycle stage in the control rats.
5. Conclusions
In conclusion, this study demonstrated that ovariectomy does not influence the cholinergic
muscarinic receptor system in the context of PPI or receptor binding density. Our results suggest
that removing peripheral ovarian hormones do not affect scopolamine-induced disruptions in PPI or
muscarinic receptor binding density. Further, it is possible that ovarian hormones may have effects on
cognition through pathways other than the cholinergic muscarinic receptor system.
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